A court ruling that stops the European Medicines Agency from releasing data from two US companies calls into question the agency’s push for transparency.
The Scientist
Most Recent
Positions for 1,600 scientists at the pharmaceutical company will be eliminated globally.
Two experts propose replacing Phase 3 trials with smaller, faster alternatives and post-market surveillance to invigorate the pharmaceutical industry.
The FDA approves an antibody-drug conjugate that effectively treats a certain type of advanced breast cancer with fewer side effects than previous drugs.
A psychiatric drug in the water can cause perch to be less social, more voracious hunters.
A magnesium supplement thought to improve brain functioning gets a small clinical trial.
GlaxoSmithKline will share long-sought, raw trial data—but access will be tightly controlled.
Pharmaceutical and biotech companies ask the US Food and Drug Administration to ensure the independence of a third-party audit of its new drug program.
A phylogenetic study of traditional plant remedies could aid drug development.
Follow The Scientist
Stay Connected with The Scientist
-
The Scientist Magazine
-
The Scientist Careers
-
Neuroscience Research Techniques
-
Genetic Research Techniques
-
Cell Culture Techniques
-
Microbiology and Immunology
-
Cancer Research and Technology
Advertisement
Current Issue
